Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Dec 04, 2007
Neuren Clinical Development Update
Dec 03, 2007
Neuren Corporate Update December 2007
Nov 12, 2007
Neuren announces reorganisation
Nov 07, 2007
NNZ-2566 successful Phase 1b trial results
Oct 31, 2007
Appendix 4C - quarterly
Oct 16, 2007
Neuren completes acquisition of Hamilton Pharmaceuticals
Oct 16, 2007
Notice under section 708A(5)(e) of the Corporations Act
Oct 16, 2007
Appendix 3B - issue of convertible notes
Oct 16, 2007
Appendix 3B - issue of shares
Oct 12, 2007
Results of Meeting
Previous
1
2
3
4
5
6
Next